Drug profile · INN
paliperidone
INVEGA
paliperidone (INVEGA) is a serotonin 2a (5-ht2a) receptor antagonist. Associated with Janssen-Cilag Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — paliperidone
- US status
- approved
- Class
- Nervous system (N05)
- Route
- ORAL
- Patents
- 1
- Programs
- 5
- Data quality
- 0.89
Quick answer
paliperidone (INVEGA) is a serotonin 2a (5-ht2a) receptor antagonist. Associated with Janssen-Cilag Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Serotonin 2a (5-HT2a) receptor antagonist
Primary target: D(2) dopamine receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is paliperidone?
paliperidone (INVEGA) is a serotonin 2a (5-ht2a) receptor antagonist. Associated with Janssen-Cilag Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for paliperidone?
INVEGA is a marketed brand name for paliperidone. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of paliperidone?
paliperidone has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.